Table 2. Bone marrow features and 2022 WHO classification for confirmed suspicions of myelodysplastic neoplasms (n=37).
| MDS features | ||
|---|---|---|
| Bone marrow blasts, median (IQR), % | 2.5 | (1.8–5.5) |
| Any bone marrow cytogenetic abnormality, n (%)* | 19/36 | (53) |
| Any bone marrow somatic mutation, n (%)† | 25/26 | (96) |
| Bone marrow flow cytometric score≥2, n (%)‡ | 26/35 | (74) |
| 2022 WHO classification, n (%) | ||
| MDS with defining genetic abnormalities | ||
| MDS with low blasts and SF3B1 mutation (MDS-SF3B1) | 4 | (11) |
| MDS with low blasts and ring sideroblasts (wild-type SF3B1) | 1 | (2.7) |
| MDS with biallelic TP53 inactivation (MDS-biTP53) | 1 | (2.7) |
| MDS morphologically defined | ||
| MDS with low blasts (MDS-LB) | 17 | (46) |
| MDS with increased blasts 1 (MDS-IB1) | 5 | (14) |
| MDS with increased blasts 2 (MDS-IB2) | 5 | (14) |
| Chronic myelomonocytic leukaemia (CMML1) | 4 | (11) |
| International Prognostic Scoring System, n (%) | ||
| Low/intermediate-1 | 29 | (78) |
| Intermediate-2/high | 8 | (22) |
| Revised International Prognostic Scoring System, n (%) | ||
| Very low/low/intermediate | 27 | (73) |
| High/very high | 10 | (27) |
*
Bone marrow karyotype was not available for one patient.
†
Molecular profiling was not available for 11 patients.
‡
Bone marrow flow cytometric24 score was computed as the number of parameters with values outside of the reference ranges among myeloblast-related cluster size in all nucleated cells (%), B-progenitor-related cluster size in all CD34+ cells (%), lymphocytes to myeloblast CD45 ratio and granulocyte to lymphocyte SSC ratio. Bone marrow flow cytometric score was not available for two patients.
MDS, myelodysplastic neoplasm.